Indicated for: psoriasis
Substance: efalizumab (monoclonal antibody)
ATC: L04AA21 (Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants)
Efalizumabum was a medication previously used for the treatment of chronic plaque psoriasis. It is a monoclonal antibody that works by inhibiting the activation and migration of T-lymphocytes, reducing inflammation and psoriasis symptoms.
The medication was administered as a subcutaneous injection, usually once a week, according to the doctor's instructions. It was effective in alleviating symptoms and improving skin appearance.
Side effects included headache, chills, nausea, and, in rare cases, severe reactions such as progressive multifocal leukoencephalopathy (PML). Its use has been discontinued in many countries due to associated risks.
Consult your doctor to discuss available alternatives for psoriasis treatment. Follow all medical recommendations to ensure the best possible care.